4791-23-5

Usage

Uses

Used in Pharmaceutical Research:
N-(Anilinocarbonyl)-2-chloroacetamide is utilized as a building block in pharmaceutical research for its capacity to participate in various chemical reactions. This makes it a valuable component in the development of new drugs, as it can be modified and combined with other compounds to create novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, N-(Anilinocarbonyl)-2-chloroacetamide serves as a key precursor for the synthesis of other organic compounds. Its unique structure allows it to be a starting point for creating a variety of complex organic molecules, which can be used in different industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Drug Development:
N-(Anilinocarbonyl)-2-chloroacetamide has potential applications in the development of new drugs. Its ability to engage in multiple chemical reactions makes it a promising candidate for creating innovative pharmaceuticals that can address unmet medical needs or improve upon existing treatments.

InChI:InChI=1/C9H9ClN2O2/c10-6-8(13)12-9(14)11-7-4-2-1-3-5-7/h1-5H,6H2,(H2,11,12,13,14)

Upstream product

• 64-10-8 phenyl carbamate 
• 79-04-9 chloroacetyl chloride 
• 4461-30-7 2-chloroacetylisocyanate 
• 62-53-3 aniline 
• 79-37-8 oxalyl dichloride 
• 79-07-2 Chloroacetamide 
• 142-04-1 aniline hydrochloride 
• 174968-74-2 6-chloromethyl 3-phenyl 2,4-dioxo 2,4-H 1,3,5-oxadiazine 
• 103-71-9 phenyl isocyanate 

Downstream Products

• 2748-37-0 N-phenyl-N'-(N-phenyl-glycyl)-urea 
• 556-90-1 pseudothiohydantoin 
• 15414-78-5 1-phenylhydantoin 
• 13562-13-5 N--N'-phenyl-harnstoff 
• 72546-75-9 morpholine-4-carbodithioic acid 4-phenyl-allophanoylmethyl ester 
• 76979-52-7 1-{2-[(4-Oxo-4H-quinazolin-3-ylmethyl)-amino]-acetyl}-3-phenyl-urea 
• 86549-37-3 2-(1H-benzoimidazol-2-ylsulfanyl)-N-phenylcarbamoyl-acetamide 
• 80416-38-2 1-[2-(4-Oxo-3-phenyl-3,4-dihydro-quinazolin-2-ylsulfanyl)-acetyl]-3-phenyl-urea 
• 76979-53-8 1-{2-[(6-Bromo-4-oxo-4H-quinazolin-3-ylmethyl)-amino]-acetyl}-3-phenyl-urea 
• 5711-53-5 O,O-diethyl (phenylaminocarbamoylcarbonylmethyl)dithiophosphate 
• 24074-40-6 O,O-diethyl (phenylaminocarbamoylcarbonylmethyl)phosphonate 
• 195820-22-5 1-[2-(Benzothiazol-2-ylsulfanyl)-acetyl]-3-phenyl-urea 
• 101-99-5 N-carboethoxyaniline 

Relevant academic research and scientific papers

Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance

P-glycoprotein (ABCB1)-mediated multidrug resistance (MDR) has become a major obstacle in successful cancer chemotherapy, which attracted much effort to develop clinically useful compounds to reverse MDR. Here, we designed and synthesized a novel series o

Preparation and biological evaluation of new antimicrotubule agents: Modification of the imidazolidin-2-one moiety of phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates

We prepared and biologically evaluated 32 novel molecules named phenyl 4-(dioxoimidazolidin-1-yl)benzenesulfonates (PID-SOs) and ethyl 2-(3-(4-(phenoxysulfonyl)phenyl)ureido)acetates (EPA-SOs). The antiproliferative activity of PID-SOs and EPA-SOs was ass

Design, Synthesis, and Antitumor Activity Evaluation of Trifluoromethyl-Substituted Pyrimidine Derivatives Containing Urea Moiety

Abstract: In order to find efficient new antitumor drugs, a series of novel pyrimidine derivatives containing urea moiety were designed and synthesized, and the antitumor activity of four human tumor cells was evaluated by MTT analysis. The results showed that most of the target compounds exhibited moderate antitumor activity. In particular, the IC50 (concentration required to achieve 50% inhibition of the tumor cell proliferation) value of compound 2-((4-(4-ethylphenoxy)-6-(trifluoromethyl)pyrimidin-2-yl)thio)-N-((4-ethylphenyl)carba-moyl)acetamide for MGC-803 (human gastric carcinoma cell line) was 2.51 ± 0.17 μmol L–1, the anti-proliferative activity was significantly better than the positive control drug 5-fluorouracil. Molecular docking revealed that this compound can bind well to the active site of epidermal growth factor receptor (EGFR), and it may become a potential antitumor drug.

A concise approach to n-substituted rhodanines through a base-assisted one-pot coupling and cyclization process

An efficient approach to obtain functionalized rhodanines was developed through a base-assisted one-pot coupling and continuous cyclization of a primary amine, carbon disulfide, and methyl (2-chloroacetyl)carbamate. This conversion tolerates a broad range of functional groups and can be used to scale the preparation of N-substituted rhodanines in excellent yields.

ANTIBACTERIAL THERAPEUTICS AND PROPHYLACTICS

The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

including ureide structural unit-5-cyano-pyrimidine derivatives and process for their preparation and use

The invention belongs to the field of medicinal chemistry, and discloses ureide structural unit-containing 5-cyano pyrimidine derivatives with antitumor activity and a preparation method and use thereof in medicine development. A pyrimidine mother nucleu is constructed from three components by one pot method, an active fragment ureide structure with antitumor activity is introduced into the mother nucleu by use of medicinal chemistry combination principles to obtain the basic skeleton of the series of compounds, and the series of ureide structural unit-containing 5-cyano pyrimidine derivatives can be prepared by chlorination and amination and other reactions. The ureide structural unit-containing 5-cyano pyrimidine derivatives have a general formula as shown in the specification, the results of evaluation in vitro antitumor activity show that the compounds have obvious inhibiting and killing effects on various tumor cells EC-109, MCF-7, MGC-803 and B16-F10, can be used as candidate or leading compounds for further development, and can be used in preparing of antitumor medicines.

Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress

We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We also evaluated selected compounds in our bimolecular complementation assay (BiMC) to detect and visualize a Marburg mVP40–Nedd4 interaction in live mammalian cells. Antiviral activity was assessed for selected compounds using a live recombinant vesicular stomatitis virus (VSV) (M40 virus) that expresses the EBOV VP40 PPxY L-domain. Finally selected compounds were evaluated in several ADME assays to have an early assessment of their drug properties. Our compounds had low nM potency in these assays (e.g., compounds 21, 24, 26, 39), and had good human liver microsome stability, as well as little or no inhibition of P450 3A4.

NOVEL ANTIVIRAL COMPOUNDS AND METHODS USING SAME

The present invention includes compounds that are useful in preventing or treating viral infections, such as viral infections caused by a filovirus, arenavirus, rhabdovirus, paramyxovirus, and/or retrovirus. The present invention further includes composit

Synthesis and antitumor activity evaluation of pyrimidine analogues bearing urea moiety

A series of 4-anilino-6-phenylpyrimidines containing urea moiety were synthesized and the structures of all products were confirmed by 1H NMR, 13C NMR and HRMS. The antiproliferative activities of these compounds were evaluated against three human tumor cell lines (MGC-803, MCF-7 and EC-109) by applying the MTT assay method. compounds 4a, 4b and 6a showed the most effective activity, among which, 6a was more cytotoxic than 5-fluorouracil against all tested human cancer cell lines with IC50 values ranging from 1.80 to 2.72 μmol·L-1. A series of 4-anilino-6-phenylpyrimidines containing urea moiety were synthesized. The antiproliferative activities of these compounds were evaluated against three human tumor cell lines (MGC-803, MCF-7 and EC-109) by applying the MTT assay method. compounds 4a, 4b and 6a showed most effective activity, among which, 6a was more cytotoxic than 5-fluorouracil against all tested three human cancer cell lines with IC50 values ranging from 1.80 to 2.72 μmol·L-1. Copyright

Selective alkylation of βII-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents

Aryl chloroethylureas (CEUs) are potent anti-neoplastic agents alkylating specific intracellular proteins such as βII-tubulin. Recently we have identified a new subset of CEU derived from compound 36 that alkylates thioredoxin isoform 1 (Trx-1), inhibits the nuclear translocation of Trx-1, and favors the accumulation of cells in G0/G1 phase. We have evaluated the effects of various substituents and their position on the aromatic ring of a series of derivatives of 36 on (i) the anti-proliferative activity, (ii) the cell cycle progression, (iii) the nuclear translocation of Trx-1, and (iv) their covalent binding to β-tubulin. The same experiments were performed on representative CEU derivatives where the 2-chloroethyl amino moiety is replaced by either an ethyl, a 2-aminooxazolinyl or a 2-chloroacetyl group. On one hand, our results suggest that CEUs substituted on the phenyl ring at position 3 or 4 by cycloalkyl and substituted cycloalkyl or cycloalkoxy groups inhibit the nuclear translocation of Trx-1 and arrest the cell cycle progression in G0/G1. On the other hand, CEUs substituted by a fused aromatic ring, an aliphatic chain, or a fused aliphatic ring are alkylating βII-tubulin but not Trx-1. Beside the expected inactivity of the ethylurea derivatives, none of the modification to the electrophilic moiety led to cross-selectivity of the drugs toward β-tubulin but increased the anti-proliferative activity and resulted in mitigated effects on Trx-1 translocation.